Kelsey Goodwin
Stock Analyst at Piper Sandler
(3.89)
# 612
Out of 4,989 analysts
23
Total ratings
57.89%
Success rate
11.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Initiates: Neutral | $21 | $20.26 | +3.65% | 1 | Aug 19, 2025 | |
| JANX Janux Therapeutics | Initiates: Overweight | $42 | $21.73 | +93.28% | 1 | Aug 19, 2025 | |
| RVMD Revolution Medicines | Initiates: Overweight | $75 | $42.53 | +76.35% | 1 | Aug 19, 2025 | |
| URGN UroGen Pharma | Initiates: Overweight | $36 | $17.23 | +108.94% | 4 | Aug 19, 2025 | |
| CGON CG Oncology | Initiates: Overweight | $55 | $36.56 | +50.46% | 1 | Aug 19, 2025 | |
| TNGX Tango Therapeutics | Initiates: Overweight | $11 | $7.99 | +37.76% | 1 | Aug 19, 2025 | |
| NUVL Nuvalent | Initiates: Overweight | $112 | $77.35 | +44.80% | 3 | Aug 19, 2025 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $36 | $10.70 | +236.45% | 1 | Aug 19, 2025 | |
| IPSC Century Therapeutics | Reiterates: Buy | n/a | $0.49 | - | 3 | Mar 28, 2025 | |
| GNLX Genelux | Initiates: Buy | $8 | $4.21 | +90.02% | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.65 | - | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $78.43 | - | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $32.70 | - | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.02 | - | 1 | Oct 31, 2022 |
Summit Therapeutics
Aug 19, 2025
Initiates: Neutral
Price Target: $21
Current: $20.26
Upside: +3.65%
Janux Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $42
Current: $21.73
Upside: +93.28%
Revolution Medicines
Aug 19, 2025
Initiates: Overweight
Price Target: $75
Current: $42.53
Upside: +76.35%
UroGen Pharma
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $17.23
Upside: +108.94%
CG Oncology
Aug 19, 2025
Initiates: Overweight
Price Target: $55
Current: $36.56
Upside: +50.46%
Tango Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $11
Current: $7.99
Upside: +37.76%
Nuvalent
Aug 19, 2025
Initiates: Overweight
Price Target: $112
Current: $77.35
Upside: +44.80%
Bicara Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $10.70
Upside: +236.45%
Century Therapeutics
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.49
Upside: -
Genelux
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $4.21
Upside: +90.02%
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.65
Upside: -
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $78.43
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $32.70
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.02
Upside: -